Loading...
01/11 11:50
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reflects strong financial performance with a significant increase in net income and improved margins, despite some economic concerns. The Q&A section reveals optimism in new product opportunities and market expansion, though management was vague on certain details. Overall, the positive financial results and growth potential suggest a likely positive stock price reaction.
Q4 2024 Net Revenue $3.9 million, a 19% increase over Q4 2023, reflecting strong growth in programmatic business, offset by a decline in emergency response business.
Full Year 2024 Net Revenue $14.2 million, steady compared to 2023, with 9% growth in programmatic business, offset by a decline in emergency response business.
Q4 2024 Gross Margins 64%, an improvement of 2 percentage points from 62% in Q4 2023, due to more favorable terms with the largest supplier.
Full Year 2024 Gross Margins 62%, a 3 percentage point improvement from 59% in 2023, attributed to more favorable supplier terms.
Q4 2024 Research and Development Expenses $252,000, up from $208,000 in Q4 2023, due to an increase in headcount.
Full Year 2024 Research and Development Expenses $906,000, compared to $873,000 in 2023, reflecting higher headcount.
Q4 2024 Sales, General and Administrative Expenses $1.9 million, a decrease of 22% from $2.4 million in Q4 2023, due to a decline in bonuses, commissions, and stock compensation expense.
Full Year 2024 Sales, General and Administrative Expenses $7.7 million, down from $8.9 million in 2023, primarily due to a decrease in bonuses, commissions, and professional fees.
Q4 2024 Net Income $349,000, compared to a net loss of $654,000 in Q4 2023, marking a significant turnaround.
Full Year 2024 Net Income $74,000, compared to a net loss of $1.6 million in 2023, indicating improved financial performance.
Q4 2024 Adjusted EBITDA Positive $466,000, compared to a loss of $51,000 in Q4 2023, reflecting improved operational performance.
Full Year 2024 Adjusted EBITDA Positive $533,000, versus a loss of $76,000 in 2023, showing a significant improvement.
Q4 2024 Net Cash Provided by Operating Activities $1.3 million, an improvement of $1.5 million from net cash used of $200,000 in Q4 2023, primarily due to positive net income and changes in inventory and accounts payable.
Full Year 2024 Net Cash Used in Operations $492,000, compared to net cash provided by operations of $827,000 in 2023, a decrease of $1.3 million, primarily due to increases in inventory and accounts receivable.
Cash Balance as of December 31, 2024 $3.8 million, compared to $4.3 million as of December 31, 2023, indicating a decrease in cash balance year-over-year.
New Product Launch: Launch of the 20-inch HydraGuard UltraFilter designed for higher volume water applications, targeting sterile processing, laboratories, and manufacturing.
Market Expansion: Added nearly 600 new customer sites contributing almost $2 million in sales, accounting for over 13% of annual revenue.
Operational Efficiency: Achieved profitability for the first time in Q3 2024, with gross margins increasing to 64% in Q4 2024.
Strategic Shift: Focus on expanding into new markets and leveraging regulatory challenges to drive demand.
Emergency Response Business Decline: A significant decline in the emergency response business was noted in the first half of 2024, with sales contributions dropping to single-digits, impacting overall revenue.
Regulatory Challenges: The company faces existing and new regulatory requirements that could affect its business operations and commercialization efforts.
Market Adoption Rate: The rate of adoption of Nephros' products and services by hospitals and healthcare providers is a critical factor that may influence revenue growth.
Economic Factors: Economic conditions and competitive pressures are mentioned as potential risks that could impact Nephros' financial performance.
Supply Chain Issues: The company has benefited from more favorable terms with its largest supplier, but any changes in supply chain dynamics could pose risks.
Product Launch: Launch of the 20-inch HydraGuard UltraFilter designed for higher volume water applications, targeting sterile processing, laboratories, and manufacturing.
Market Expansion: Commitment to expanding into new markets and leveraging regulatory challenges to drive demand.
Customer Growth: Added nearly 600 new customer sites contributing almost $2 million in sales, accounting for over 13% of annual revenue.
Revenue Growth: Expecting continued growth trajectory in 2025 and beyond, building on the foundation established in 2024.
Profitability: Achieved profitability for the first time in Q3 2024, with a focus on sustaining profitability moving forward.
Gross Margins: Gross margins improved to 64% in Q4 2024, with expectations for continued improvement.
Cash Position: Cash balance of $3.8 million as of December 31, 2024, indicating a stable financial position.
Share Repurchase Program: None
Nephros shows strong financial performance with significant improvements in net income and adjusted EBITDA. The strategic expansion into underserved markets, innovative product launches, and maintaining a solid cash position are positive indicators. The Q&A highlights growth drivers in infection control and innovations tackling PFAS and microplastics, with a positive outlook on margins despite tariffs. However, lack of specific guidance on PFAS revenue and tariff impacts slightly tempers enthusiasm. Overall, the company's strategic initiatives and financial health suggest a positive stock price movement.
The earnings call highlights strong financial performance with significant revenue growth and improved profitability. While there are risks such as regulatory challenges and supply chain costs, the company's operational discipline and strategic expansion efforts are promising. The Q&A section suggests a sustainable growth model and effective resource allocation. Despite the need for sales force expansion, the overall sentiment remains positive due to strong financial metrics and optimistic guidance.
The earnings call reveals strong financial performance with increased revenue, improved margins, and positive net income, despite some economic and competitive pressures. The company's strategic initiatives, including market expansion and digital tool development, are progressing well. The Q&A section indicates potential growth opportunities, although some responses were vague. The absence of shareholder return plans is a minor negative. Overall, the positive financial results and strategic growth initiatives suggest a positive stock price movement.
The earnings call reflects strong financial performance with a significant increase in net income and improved margins, despite some economic concerns. The Q&A section reveals optimism in new product opportunities and market expansion, though management was vague on certain details. Overall, the positive financial results and growth potential suggest a likely positive stock price reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
